首例人工心脏工作良好
ANAHEIM, Nov 12 (Reuters Health) - The first man to receive a self-contained artificial heart is continuing to do well 130 days later, announced the surgeon who implanted the device known as AbioCor.
Dr. Robert D. Dowling reported here at the American Heart Association's (AHA) meeting that a total of six patients have received AbioCor implants--the most recent last Monday. That patient, a 51-year-old man, is the youngest to date and underwent the procedure at Hahnemann University in Philadelphia, Pennsylvania.
, 百拇医药
All the patients are doing well, Dowling said.
"We are very impressed with the recovery of these very critically ill patients," Dowling told AHA meeting attendees. The first patient, Robert Tools, underwent surgery at the University of Louisville Jewish Hospital, Kentucky, on July 2. Tools has even gone fishing and is touring with the city's mayor in efforts to revitalize Louisville's economy, Dowling said.
Dowling described the device, which known as a biventricular assist device, as a replacement for both the right and left ventricles, the lower chambers of the heart.
, 百拇医药
The patient's own ventricles are removed and the AbioCor is implanted, along with an internal battery with a charge time of about 30 minutes, a controller and an energy transfer device that allows the patient to "plug himself in" to any regular outlet. The electricity is transferred through the skin to the controller, a unit about the size of a large pacemaker, located near the collarbone.
Dr. O. H. Frazier of the Texas Heart Institute in Houston updated the audience on his team's experience with the Jarvik 2000, an implanted device that assists the heart's left ventricle, in 16 patients.
, http://www.100md.com
The device is implanted inside the lower heart chamber and has five speeds that the patient controls, according to activity level. The Jarvik 2000 is approved as a bridge to heart transplantation by the Food and Drug Administration in the US, but is approved in the UK as a permanent device.
Frazier noted that some degree of normalization of the heart has occurred in some recipients of the Jarvik 2000. One patient in Germany and another in the UK have improved enough to have the device removed and are remaining stable without it.
, 百拇医药
Inventor, and Frazier's colleague, Dr. Robert Jarvik is, "as we speak," at the US Food and Drug Administration with the UK patient to file for approval of the device as a destination device, Frazier reported.
Dowling told Reuters Health that "there is some talk of a competition between these two devices. We need both of them." Candidates for the Jarvik 2000 have isolated failure of their left ventricle while candidates of the AbioCor have complete disease of both ventricles, he pointed out., 百拇医药
Dr. Robert D. Dowling reported here at the American Heart Association's (AHA) meeting that a total of six patients have received AbioCor implants--the most recent last Monday. That patient, a 51-year-old man, is the youngest to date and underwent the procedure at Hahnemann University in Philadelphia, Pennsylvania.
, 百拇医药
All the patients are doing well, Dowling said.
"We are very impressed with the recovery of these very critically ill patients," Dowling told AHA meeting attendees. The first patient, Robert Tools, underwent surgery at the University of Louisville Jewish Hospital, Kentucky, on July 2. Tools has even gone fishing and is touring with the city's mayor in efforts to revitalize Louisville's economy, Dowling said.
Dowling described the device, which known as a biventricular assist device, as a replacement for both the right and left ventricles, the lower chambers of the heart.
, 百拇医药
The patient's own ventricles are removed and the AbioCor is implanted, along with an internal battery with a charge time of about 30 minutes, a controller and an energy transfer device that allows the patient to "plug himself in" to any regular outlet. The electricity is transferred through the skin to the controller, a unit about the size of a large pacemaker, located near the collarbone.
Dr. O. H. Frazier of the Texas Heart Institute in Houston updated the audience on his team's experience with the Jarvik 2000, an implanted device that assists the heart's left ventricle, in 16 patients.
, http://www.100md.com
The device is implanted inside the lower heart chamber and has five speeds that the patient controls, according to activity level. The Jarvik 2000 is approved as a bridge to heart transplantation by the Food and Drug Administration in the US, but is approved in the UK as a permanent device.
Frazier noted that some degree of normalization of the heart has occurred in some recipients of the Jarvik 2000. One patient in Germany and another in the UK have improved enough to have the device removed and are remaining stable without it.
, 百拇医药
Inventor, and Frazier's colleague, Dr. Robert Jarvik is, "as we speak," at the US Food and Drug Administration with the UK patient to file for approval of the device as a destination device, Frazier reported.
Dowling told Reuters Health that "there is some talk of a competition between these two devices. We need both of them." Candidates for the Jarvik 2000 have isolated failure of their left ventricle while candidates of the AbioCor have complete disease of both ventricles, he pointed out., 百拇医药